Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics" but filing content confirms Prana Biotechnology Limited).
Reporting Period: Financial year ended 30 June 2014.
Filing Date: 29 August 2014.
Principal Activities: Commercialization of research into Alzheimer's Disease, Huntington's Disease, and other age-related degenerative disorders. The company is in a development stage with no commercial product revenue.
Key Financial Metrics
| Metric | 2014 (A$) | 2013 (A$) |
|---|---|---|
| Revenue (Interest income only) | 363,775 | 150,867 |
| Net Loss (Attributable to members) | (13,329,239) | (7,787,242) |
| Other Income (R&D Tax Incentive) | 7,845,396 | 4,488,526 |
| Research & Development Expenses | (14,908,098) | (8,586,437) |
| Cash and Cash Equivalents (End of Period) | 34,167,018 | 13,346,760 |
| Net Tangible Assets | 37,686,287 | 13,974,713 |
| Net Tangible Assets per Share (Cents) | 7.71 | 3.66 |
| Loss per Share (Basic/Diluted Cents) | (3.11) | (2.30) |
Material Changes vs. Prior Period
- Revenue: Increased 141.12% to A$363,775, driven entirely by higher interest received on bank accounts.
- Net Loss: Increased 71.17% to A$13.3 million. This increase is primarily due to a 73.62% rise in R&D expenses (A$14.9 million vs A$8.6 million), partially offset by a significant increase in R&D tax incentive refunds.
- R&D Expenses: The increase is attributable to the completion of Phase II studies for Alzheimer's ("IMAGINE") and Huntington's ("Reach2HD"), pre-Phase III development costs, and pre-clinical development of the Parkinson's candidate PBT434.
- Liquidity: Cash reserves more than doubled from A$13.3 million to A$34.2 million, supported by capital raising activities and option exercises.
- Capital Structure: Issued 12.2 million ADSs under an At-The-Market (ATM) facility for gross proceeds of A$39.37 million. Additionally, 20.9 million options were exercised, generating A$4.95 million.
Outlook, Management Commentary, and Risks
Clinical Trial Updates
- Huntington's Disease (Reach2HD): Phase 2a trial results showed PBT2 was safe and well-tolerated. Significant improvement was observed in the Executive Function Composite cognitive measure at 12 weeks (p=0.005) and trended at 26 weeks. MRI data suggested a slower rate of brain cortical tissue thinning in treatment groups compared to placebo.
- Alzheimer's Disease (IMAGINE): Phase 2 trial showed no significant change in beta-amyloid burden. However, there was a trend towards preserving hippocampal volume in treated patients. Safety profile remained equivalent to placebo over 52 weeks.
- Parkinson's Disease (PBT434): Pre-clinical data presented at the 17th Movement Disorders Congress showed prevention of alpha-synuclein aggregation. Development is progressing toward first-in-man studies in 2015.
Financial Outlook and Liquidity
Management believes the company is a going concern. Cash on hand plus subsequent inflows are sufficient to meet forecast outflows for at least 12 months. Future funding options include:
- Continued use of the ATM facility (up to US$48.73 million available).
- Exercise of 18.77 million unlisted options (potential A$6.9 million).
- Receipt of A$7.3 million R&D tax refund receivable from the Australian Tax Office.
- Ability to scale down operations if necessary.
Risks and Contingencies
- Development Risk: The company is pre-revenue and dependent on the success of clinical trials. Actual outcomes may differ from forward-looking statements.
- Capital Requirements: Continued reliance on equity financing and government tax incentives to fund operations.
- Audit Status: Accounts are currently in the process of being audited; the final Annual Report will be provided in due course.
Investor Verification Checklist
- Cash Runway: Verify the timing of the expected A$7.3 million R&D tax refund and the sustainability of the A$34.2 million cash balance against projected R&D burn rates.
- Clinical Data: Review the full statistical analysis of the "Reach2HD" and "IMAGINE" trials, specifically the significance of the "trends" reported in the Alzheimer's study.
- Dilution: Assess the impact of the 18.77 million outstanding options and the remaining capacity under the ATM facility on future share price dilution.
- Regulatory Path: Confirm the timeline and requirements for the proposed first-in-man studies for PBT434 in 2015.
- Audit Confirmation: Await the final audited Annual Report to confirm the preliminary figures and ensure no material adjustments are made.